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Editorials

Treatment of people diagnosed with chronic hepatitis C virus infection
Marc Bulterysa & Saeed Sadiq Hamidb
In 2015, 71 million people worldwide
were living with one of the six major
genotypes of hepatitis C virus (HCV)
and 399 000 people died from the
infection.1 The 2016 World Health Organization (WHO) guidelines for the
screening, care and treatment of people
with chronic hepatitis C virus infection2
focused on two points. First, WHO
recommended considering all infected
adults, that is, 18 years of age or older, for
treatment, but prioritizing those at highest risk of death or disability or those
at high risk of transmitting the virus.
Second, WHO recommended treating
patients with direct-acting antivirals,
using different regimens depending on
hepatitis C virus genotype.
Since then, three key developments
prompted changes in terms of when to
treat and what treatment to use. First,
safe and highly effective direct acting
antiviral regimens that improve the
balance of benefit-to-harm of treating
people with little or no hepatic fibrosis
became the norm for the treatment
of all patients. Second, several new,
pan-genotypic direct acting antiviral
medicines became available, reducing
the need for genotyping to guide treatment decisions. Third, the price of direct
acting antivirals has fallen considerably,
which enabled a more rapid roll-out of
treatment in low- and middle-income
countries.3
Ne w W H O g u i d e l i n e s w e r e
launched on World Hepatitis Day4 in
July 2018. These guidelines are intended
for public health officials to use as the
basis for developing national hepatitis
policies, plans and treatment guidelines.
WHO formulated population, intervention, comparator and outcome
(PICO) questions that addressed when
to start treatment and what treatment
to use. These questions were considered
for adults 18 years of age or older, adolescents 12–17 years of age and children
younger than 12 years. WHO commissioned systematic reviews, convened

a guidelines development group in
September 2017, drafted the guidelines
and submitted them to peer review and
ultimately for clearance by the WHO
Guidelines Review Committee.
The 2018 guidelines offer new recommendations in the treatment of hepatitis C virus. First, WHO recommends
offering treatment to all adolescents and
adults diagnosed with chronic hepatitis
C virus infection, with the exception of
pregnant women, irrespective of disease
stage. Second, the guidelines recommend the use of pangenotypic direct
acting antivirals in adults. This includes
those who have never been treated with
direct-acting antivirals and those who
previously received interferon and/or
ribavirin. These regimens and the duration of treatment depend on the presence or absence of cirrhosis. In adolescents, WHO recommends direct-acting
antiviral-based regimens that are still
genotype-dependent. Treatment in adolescents still requires non pangenotypic
regimens, and ribavirin for treatment
of genotype 2 and 3. Third, in children
diagnosed with chronic hepatitis C virus
infection, WHO recommends deferring treatment until children reach 12
years of age. None of the recommended
pangenotypic direct acting antiviral
regimens for adults are yet approved
for use in adolescents and children, but
approval is anticipated in 2019.
The implications of these new WHO
recommendations for public health are
threefold. First, treating all persons infected will allow faster progress towards
hepatitis C virus elimination as a major
public health threat by 2030.5 Second,
the use of pangenotypic regimens removes the need for expensive genotyping before treatment initiation. Third,
treatment of adolescents means that
more people could become adults free
of hepatitis C virus infection. Further
efforts to increase testing, especially in
populations most affected by hepatitis
C, will contribute to identifying those

infected and in need of treatment.6 Five
population groups (people who inject
drugs, people in prisons or other closed
settings, men who have sex with men,
sex workers and indigenous populations) require specific public health
approaches because of stigma and discrimination, vulnerability and difficulties in accessing services. Treating all
persons diagnosed with hepatitis C virus
infection using pangenotypic direct acting antiviral regimens will simplify care
and facilitate achieving viral hepatitis
elimination as established in the Global
health sector strategy on viral hepatitis,
approved in 2016.5 ■
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